From September 1988 two hundred -sixty seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus FMACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse-free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs. 42%). The degree of hemathological and non-hematological toxicity was similar in both regimens More reliable conclusions will be drawn after a longer follow-up.
MACOP-B vs F. MACHOP in the treatment of high-grade non-Hodgkin's lymphomas / S., Tura; Mandelli, Franco; P., Mazza; S., Pileri; F., Gherlinzoni; M., Bocchia; P. L., Zinzani; M., Fiacchini; Martelli, Maurizio; G., Papa; M., Antimi; M. F., Martelli; F., Grignani; B., Falini; F., Calabresi; E. M., Ruggeri; F., Damacco; V. M., Lauta; G., Lucarelli; L., Moretti. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 5 (SUPPL. 1):(1991), pp. 74-78.
MACOP-B vs F. MACHOP in the treatment of high-grade non-Hodgkin's lymphomas
MANDELLI, Franco;MARTELLI, Maurizio;
1991
Abstract
From September 1988 two hundred -sixty seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus FMACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse-free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs. 42%). The degree of hemathological and non-hematological toxicity was similar in both regimens More reliable conclusions will be drawn after a longer follow-up.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
